- Home
- MBRX
as 04-24-2025 11:38am EST
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 11.3M | IPO Year: | 2016 |
| Target Price: | $6.00 | AVG Volume (30 days): | 349.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.40 - $5.47 | Next Earning Date: | 05-09-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Moleculin Biotech Inc. News
MBRX Breaking Stock News: Dive into MBRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
TipRanks
22 days ago
Moleculin Biotech doses first patient in Phase 3 MIRACLE trial
Clinical Trials Arena
22 days ago
Moleculin Biotech begins dosing subjects in combination therapy trial for AML
Zacks
23 days ago
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now
GlobeNewswire
23 days ago
Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial
Zacks
a month ago
All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy
GuruFocus.com
a month ago
Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ...
Thomson Reuters StreetEvents
a month ago
Q4 2024 Moleculin Biotech Inc Earnings Call
Compare MBRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MBRX Moleculin Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.